What is 4basebio?
4basebio is a biotechnology firm specializing in the design and manufacture of Good Manufacturing Practice (GMP)-grade synthetic DNA and non-viral nanoparticles. These proprietary technologies are engineered for efficient gene delivery, offering distinct advantages over conventional plasmid DNA and non-targeted lipid nanoparticles. The company's solutions are tailored for critical applications in gene therapy, DNA vaccines, gene editing, and targeted delivery systems, serving pharmaceutical and biotechnology companies that require advanced gene synthesis and delivery capabilities.
How much funding has 4basebio raised?
4basebio has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2025): $1.6M with participation from Government of Canada
Key Investors in 4basebio
Government of Canada
The Government of Canada is the federal governing body of Canada, responsible for public services and programs. Its official digital portal, Canada.ca, provides access to a wide range of government information and resources for citizens and businesses.
What's next for 4basebio?
The recent major strategic investment signals a pivotal growth phase for 4basebio, likely enabling the company to scale its manufacturing operations, expand its research and development initiatives, and accelerate the commercialization of its gene delivery technologies. This infusion of capital is expected to bolster its position in the competitive gene therapy and vaccine markets, potentially leading to new partnerships and clinical advancements.
See full 4basebio company page
